bioMerieux S.A. chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 29.29
Dividend & YieldN/A£ (N/A)
Beta 0.14
Market capitalization N/A
Operating cash flow 676.2M
ESG Scores 23.6

Company description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 13.1M 32.9M 4.7M 24.2M
Total Cashflows From Investing Activities -413.1M -282.2M -265.2M -307.3M
Net Borrowings 105.5M -69.2M -134.5M -50.1M
Total Cash From Financing Activities 43M -133.9M -176.2M -127M
Change To Operating Activities 36.3M 28.5M 77.9M -21.8M
Issuance Of Stock
Net Income 256.5M 272.8M 404.4M 601.1M
Change In Cash 17.8M -14.3M 107.3M 416M
Effect Of Exchange Rate -11.8M -6.1M -34.1M 39.2M
Total Cash From Operating Activities 399.8M 407.9M 582.8M 811.1M
Depreciation 176.8M 187M 208.8M 230.9M
Change To Account Receivables -30.6M -57.3M -80.4M 23.6M
Other Cashflows From Financing Activities -23.4M -23.4M -800k
Change To Netincome -45.1M -5.6M 30.7M -1.4M
Capital Expenditures -226.4M -272.5M -277.5M -290.1M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 326.9M 374.3M 398.8M 389M
Income Before Tax 320.5M 347.5M 524.2M 773.8M
Net Income 256.5M 272.8M 404.4M 601.1M
Selling General Administrative 643.1M 749.8M 789.3M 818.3M
Gross Profit 1.3B 1.47B 1.75B 1.96B
Ebit 363.5M 388.4M 612.5M 801M
Operating Income 363.5M 388.4M 612.5M 801M
Interest Expense -19.7M -20.1M -24.9M -9.1M
Income Tax Expense 65.1M 77.8M 121.5M 175.6M
Total Revenue 2.42B 2.67B 3.12B 3.38B
Cost Of Revenue 1.12B 1.21B 1.36B 1.41B
Total Other Income ExpenseNet -43M -40.9M -88.3M -27.2M
Net Income From Continuing Ops 255.4M 269.7M 402.7M 598.2M
Net Income Applicable To Common Shares 256.5M 272.8M 404.4M 601.1M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 1.5B 1.53B 1.45B 1.44B
Total Stockholder Equity 1.93B 2.2B 2.43B 3.12B
Other Current Liabilities 225.1M 236.3M 260.4M 298.7M
Total Assets 3.5B 3.78B 3.93B 4.62B
Common Stock 12M 12M 12M 12M
Other Current Assets 15.5M 14M 27.6M 43.7M
Retained Earnings 256.5M 272.8M 404.4M 1.21B
Treasury Stock 1.6B 1.86B 1.95B 1.84B
Cash 288.3M 275M 389.2M 803.5M
Total Current Liabilities 796.3M 1.17B 923.8M 955.8M
Other Stockholder Equity 1.63B 1.86B 1.97B 1.85B
Property, Plant, and Equipment 899.1M 1.03B 1.07B 1.22B
Total Current Assets 1.31B 1.44B 1.66B 2.21B
Net Tangible Assets 799M 1.04B 1.37B 2.04B
Net Receivables 578.4M 639.9M 682.1M 701.4M
Accounts Payable 179.7M 211.9M 207.1M 239.5M


Insider Transactions

Here are the insider transactions of stock shares related to bioMerieux S.A.:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to bioMerieux S.A.. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on bioMerieux S.A.

Here is the result of two systematic investment strategies applied to bioMerieux S.A.. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on bioMerieux S.A.

The following chart shows the equity curve of the two systematic investment strategies applied to bioMerieux S.A.:

bioMerieux S.A. automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on bioMerieux S.A.

This is the result of two momentum investment strategies applied to bioMerieux S.A.. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on bioMerieux S.A.

The following chart shows all the entries opened by the momentum investment system on bioMerieux S.A.:

bioMerieux S.A. momentum entries
  • The first momentum investment strategy would give 2.56% of return on bioMerieux S.A.. That represents 5.35£ of latent gain with 209.3£ of employed capital.
  • The second momentum investment strategy would give 0% of return on bioMerieux S.A.. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

2.56 %

Latent gain

5.35 £

Invested capital

209.3 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on bioMerieux S.A.

The following chart shows the equity curve of the two momentum strategies applied to bioMerieux S.A.:

bioMerieux S.A. momentum equity

Note: the dividends potentially given by bioMerieux S.A. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on bioMerieux S.A.

The following chart shows the employed capital evolution of the two momentum strategies on bioMerieux S.A. since the beginning:

bioMerieux S.A.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on bioMerieux S.A.

Buy the dip entry openings on bioMerieux S.A.

bioMerieux S.A.

The performance achieved by the robo-advisor on bioMerieux S.A. is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows bioMerieux S.A. stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of bioMerieux S.A., and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to bioMerieux S.A.

The following chart shows the result of the investment strategy applied to bioMerieux S.A.:

bioMerieux S.A.

Note: the dividends potentially given by bioMerieux S.A. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on bioMerieux S.A.

The following chart shows the employed capital evolution since the beginning of the investment strategy on bioMerieux S.A.:

bioMerieux S.A.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on bioMerieux S.A.

In this section, I will compare the three previous investment strategies applied to bioMerieux S.A..

Equity curve comparison on bioMerieux S.A.

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

bioMerieux S.A. investment strategy comparison

Employed capital comparison on bioMerieux S.A.

bioMerieux S.A. investment comparison

Performance comparison on bioMerieux S.A.

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter 2.56% 5.35£ 209.3£ 42.67%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with bioMerieux S.A.:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between bioMerieux S.A. and the other stocks. There may be false positives or some missing correlated stocks. If the price of bioMerieux S.A. does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name bioMerieux S.A.
Country France
City Marcy l'Étoile
Address 376 Chemin De l’Orme
Phone 33 4 78 87 20 00
Website www.biomerieux.com
FullTime employees 12084
Industry
Sector
Exchange XLON
Ticker 0RUG.XLON
Market www.londonstockexchange.com

bioMerieux S.A. ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 3.4
Peer Environment Performance 2.2440350877193
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 11.7
Peer Social Performance 12.085087719298
Social Percentile unknown
Highest Controversy 0
Peer Highest Controversy Performance 1.9310344827586
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic no
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 8.5
Peer Governance Performance 7.7398245614035
Governance Percentile unknown

ESG at glance
Total ESG Scores: 23.6
Environment Score: 3.4
Social Score: 11.7
Governance Score: 8.5

ESG Performance: AVG_PERF

Peer Group: Healthcare

Peer Esg Score Performance: 22.091551724138

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 39